Extended indication Extension of indication to add the use of romiplostim in adult patients who have had idiopathic thrombocytopenic purpura (ITP) for ≤ 12 months and who
Therapeutic value No judgement
Registration phase Registration application pending

Product

Active substance Romiplostim
Domain Cardiovascular diseases
Reason of inclusion Indication extension IND
Main indication Other non-oncological hematological medications
Extended indication Extension of indication to add the use of romiplostim in adult patients who have had idiopathic thrombocytopenic purpura (ITP) for ≤ 12 months and who have had an insufficient response to corticosteroids or immunoglobulins.
Proprietary name Nplate
Manufacturer Amgen
Mechanism of action Unknown
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity Unknown
ATMP Unknown
Submission date June 2020
Expected Registration April 2021
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No judgement

This assessment does not indicate any potential inclusion in the package.

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

References medicijnkosten.nl
Additional remarks Gemiddelde prijs per 1 injectieflacon NPLATE, 125 μg POEDER VOOR INJECTIEVLOEISTOF 125UG € 393,61

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information